Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 25.4 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human IL-2 R beta Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Human IL-2 R beta Protein, His Tag (Cat. No. CD2-H5221) captured on CM5 chip via anti-His antibody, can bind Human IL-2, premium grade (Cat. No. IL2-H5215) with an affinity constant of 1.62 μM as determined in a SPR assay (Biacore T200) (QC tested).
Human IL-2 R beta Protein, His Tag (Cat. No. CD2-H5221) captured on CM5 chip via anti-His antibody, can bind Human IL-15, premium grade (Cat. No. IL5-H4117) with an affinity constant of 21.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Human IL-2 R beta Protein, His Tag (Cat. No. CD2-H5221) on HIS1K Biosensor, can bind Human IL-2, Tag Free with an affinity constant of 0.46 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Human IL-2 R beta Protein, His Tag (Cat. No. CD2-H5221) inhibits the IL-15-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.38-0.45 µg/mL (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Bempegaldesleukin | BMS-986321; ONO-7911; NKTR-214 | Phase 3 Clinical | Nektar Therapeutics | Coronavirus Disease 2019 (COVID-19); Melanoma; Glioma; Lymphoma; Sarcoma, Ewing; Brain Neoplasms; Neuroblastoma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Ependymoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rhabdomyosarcoma; Head and Neck Neoplasms; Leukemia; Medulloblastoma; Solid tumours | Details |
Nanrilkefusp alfa | SO-C101; RLI-15; CYP-0150; SOT-101 | Phase 2 Clinical | Microsatellite instability-high cancer; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Thymus Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Prostatic Neoplasms, Castration-Resistant; Thyroid Diseases; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Anus Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms | Details | |
GI-101 | SIM-323; SIM323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Vaginal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Vulvar Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
THOR-707 | THOR-707; SAR-444245 | Phase 2 Clinical | Synthorx Inc | Oropharyngeal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Esophageal adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Intestinal Neoplasms; Mesothelioma; Skin Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Head and Neck Neoplasms | Details |
IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Neoplasms; Lymphoma, Non-Hodgkin | Details |
IAP-0971 | IAP-0971 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms; Urinary Bladder Neoplasms | Details |
TransCon IL-2 β/γ | Phase 2 Clinical | Ascendis Pharma A/S | Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Neoplasm Metastasis | Details | |
MDNA-11 | MDNA-11; MDNA11 | Phase 2 Clinical | Medicenna Therapeutics Corp | Triple Negative Breast Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Skin Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Stomach Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Gastrointestinal Diseases; Carcinoma, Basal Cell; Ovarian Neoplasms; Skin Melanoma | Details |
Simlukafusp alfa | FAP-IL2v; RG-7461; aFAP-IL2v; RO-6874281; FAP-IL2v FP | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Breast Neoplasms; Uterine Cervical Neoplasms; Melanoma | Details |
BJ-001(Boji Biomedical Technology) | BJ-001 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours; Communicable Diseases; Neoplasm Metastasis | Details |
STK-009 | STK-009 | Phase 1 Clinical | Synthekine Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
FB-102 | FB-102; FB102 | Phase 1 Clinical | Forte Biosciences Inc | Alopecia Areata; Graft vs Host Disease; Vitiligo; Malabsorption Syndromes | Details |
NL-201 (Neoleukin Therapeutics) | NL-201 | Phase 1 Clinical | Neoleukin Therapeutics Inc | Solid tumours | Details |
Recombinant human interleukin 15(Beijing Kawin) | Phase 1 Clinical | Beijing Kawin Technology Share-Holding Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.